Benign prostatic hyperplasia (BPH): Nursing process (ADPIE)

2,037views

Benign prostatic hyperplasia (BPH): Nursing process (ADPIE)

gap test med surg

gap test med surg

Aortic aneurysm: Nursing process (ADPIE)
Coronary artery disease (CAD) and angina pectoris: Nursing process (ADPIE)
Hypertension: Nursing process (ADPIE)
Left-sided heart failure: Nursing process (ADPIE)
Myocardial infarction (MI): Nursing process (ADPIE)
Pericardial effusion and cardiac tamponade: Nursing process (ADPIE)
Rheumatic heart disease: Nursing process (ADPIE)
Antihyperlipidemics - Statins: Nursing pharmacology
Calcium-channel blockers: Nursing pharmacology
Angiotensin II receptor blockers (ARBs): Nursing pharmacology
Angiotensin-converting enzyme (ACE) inhibitors: Nursing pharmacology
Antihyperlipidemics - Miscellaneous: Nursing pharmacology
Diabetes insipidus: Nursing process (ADPIE)
Diabetes mellitus (DM): Nursing process (ADPIE)
Diabetic ketoacidosis (DKA): Nursing process (ADPIE)
Hyperosmolar hyperglycemic state (HHS): Nursing process (ADPIE)
Hyperthyroidism: Nursing process (ADPIE)
Hypothyroidism: Nursing process (ADPIE)
Syndrome of inappropriate antidiuretic hormone (SIADH): Nursing process (ADPIE)
Medications for antidiuretic hormone (ADH) disorders: Nursing pharmacology
Medications for thyroid disorders: Nursing pharmacology
Non-insulin injectable antidiabetic drugs - GLP-1 agonists and amylinomimetics: Nursing pharmacology
Oral antidiabetic medications - Alpha-glucosidase inhibitors: Nursing pharmacology
Oral antidiabetic medications - Biguanides and thiazolidinediones: Nursing pharmacology
Oral antidiabetic medications - DPP-4 inhibitors: Nursing pharmacology
Oral antidiabetic medications - Sulfonylureas and meglitinides: Nursing pharmacology
Oral antidiabetic medications - Sodium-glucose co-transporter-2 (SGLT-2) inhibitors: Nursing pharmacology
Insulin: Nursing pharmacology
Medications for growth hormone disorders: Nursing pharmacology
Epistaxis: Nursing process (ADPIE)
Eye injury: Nursing process (ADPIE)
Glaucoma: Nursing process (ADPIE)
Tonsillitis: Nursing process (ADPIE)
Antiglaucoma medications: Nursing pharmacology
Eye anesthetics: Nursing pharmacology
Mydriatics and cycloplegics: Nursing pharmacology
Ophthalmic anti-inflammatories and anti-infectives: Nursing pharmacology
Appendicitis: Nursing process (ADPIE)
Celiac disease: Nursing process (ADPIE)
Cirrhosis: Nursing process (ADPIE)
Gastroesophageal reflux disease (GERD): Nursing process (ADPIE)
Hiatal hernia: Nursing process (ADPIE)
Pancreatitis: Nursing process (ADPIE)
Peptic ulcer disease (PUD): Nursing process (ADPIE)
Antacids: Nursing pharmacology
Antidiarrheals: Nursing pharmacology
Laxatives: Nursing pharmacology
Weight loss medications: Nursing pharmacology
Antiemetics: Nursing pharmacology
Gallstone-dissolving agents: Nursing pharmacology
Gastric mucosal protective agents: Nursing pharmacology
Antispasmodics (GI): Nursing pharmacology
Histamine H2 antagonists: Nursing pharmacology
Proton pump inhibitors (PPIs): Nursing pharmacology
Treatment for Helicobacter pylori: Nursing pharmacology
Diuretics - Osmotic and carbonic anhydrase inhibitors: Nursing pharmacology
Cholinergic therapy (GU): Nursing pharmacology
Acute kidney injury (AKI): Nursing process (ADPIE)
Benign prostatic hyperplasia (BPH): Nursing process (ADPIE)
Urinary incontinence - Stress: Nursing process (ADPIE)
Urinary tract infections (UTIs): Nursing process (ADPIE)
Hemophilia: Nursing process (ADPIE)
Leukemia: Nursing process (ADPIE)
Sickle cell disease: Nursing process (ADPIE)
Anticoagulants - Heparin: Nursing pharmacology
Antiplatelet agents: Nursing pharmacology
Hemostatics: Nursing pharmacology
Iron preparations: Nursing pharmacology
Thrombolytics: Nursing pharmacology
Antihyperlipidemics - Fibrates: Nursing pharmacology
Blood products: Nursing pharmacology
Antihyperlipidemics - Bile acid sequestrants and cholesterol absorption inhibitors: Nursing pharmacology
Anticoagulants - Direct thrombin and factor Xa inhibitors: Nursing pharmacology
Anaphylaxis: Nursing process (ADPIE)
Lyme disease: Nursing process (ADPIE)
Vaccines: Nursing pharmacology
Immunoglobulins: Nursing pharmacology
Immunosuppressants for autoimmune diseases: Nursing pharmacology
Atopic dermatitis: Nursing process (ADPIE)
Frostbite: Nursing process (ADPIE)
Methicillin-resistant Staphylococcus aureus (MRSA): Nursing process (ADPIE)
Pressure injury: Nursing process (ADPIE)
Debridement agents: Nursing pharmacology
Keratolytics: Nursing pharmacology
Antibiotics - Topical: Nursing pharmacology
Antifungals - Topical: Nursing pharmacology
Corticosteroids - Topical: Nursing pharmacology
Acute compartment syndrome: Nursing process (ADPIE)
Fractures: Nursing process (ADPIE)
Gout: Nursing process (ADPIE)
Musculoskeletal injuries: Nursing process (ADPIE)
Rheumatoid arthritis (RA): Nursing process (ADPIE)
Acetylcholinesterase inhibitors for myasthenia gravis: Nursing pharmacology
Analgesics: Nursing pharmacology
Antiepileptics: Nursing pharmacology
Medications for Alzheimer disease: Nursing pharmacology
Skeletal muscle relaxants: Nursing pharmacology
Medications for migraines: Nursing pharmacology
Meningitis: Nursing process (ADPIE)
Parkinson disease: Nursing process (ADPIE)
Seizure disorder: Nursing process (ADPIE)
Stroke: Nursing process (ADPIE)
Trigeminal neuralgia: Nursing process (ADPIE)
Breast cancer: Nursing process (ADPIE)
Tumor lysis syndrome (TLS): Nursing Process (ADPIE)
Plant extracts for chemotherapy: Nursing pharmacology
Antitumor antibiotics: Nursing pharmacology
Alkylating agents: Nursing pharmacology
Peripheral arterial disease (PAD): Nursing process (ADPIE)
Peripheral venous disease (PVD): Nursing process (ADPIE)
Candidiasis: Nursing process (ADPIE)
Gonorrhea and chlamydia: Nursing process (ADPIE)
Pelvic inflammatory disease (PID): Nursing process (ADPIE)
Asthma: Nursing process (ADPIE)
Bacterial pneumonia: Nursing process (ADPIE)
Carbon monoxide poisoning: Nursing process (ADPIE)
Chronic obstructive pulmonary disease (COPD): Nursing process (ADPIE)
Epiglottitis: Nursing process (ADPIE)
Foreign body aspiration and upper airway obstruction: Nursing process (ADPIE)
Laryngotracheobronchitis (LTB) and croup: Nursing process (ADPIE)
Smoke inhalation injury: Nursing process (ADPIE)
Venous thromboembolism (VTE): Nursing process (ADPIE)
Antihistamines: Nursing pharmacology
Bronchodilators: Nursing pharmacology
Corticosteroids - Inhaled: Nursing pharmacology
Mast cell stabilizers - Inhaled: Nursing pharmacology
Leukotriene modifiers: Nursing pharmacology
Medications to control airway secretions: Nursing pharmacology
Oxygen therapy: Nursing pharmacology

Notes

BENIGN PROSTATIC HYPERPLASIA (BPH)

KEY POINTS
NOTES
PATIENT REPORT
  • 68-year-old man
  • Frequent urge to urinate, weak stream

PATHOPHYSIOLOGY
  • BPH
    • Noncancerous cells in prostate gland increase in number 
    • Prostate enlarges and compresses urethra
    • Flow of urine obstructed 
  • Causes
    • Not well understood
  • Signs and symptoms
    • Asymptomatic
    • Symptomatic
      • Urinary urgency
      • Urinary hesitancy
      • Weak stream
      • Dribbling or straining
      • Nocturia
  • Complications
    • Kidney failure
    • Kidney stones
    • Urinary tract infections
    • Prostatitis 

DIAGNOSIS AND TREATMENT
  • Diagnosis
    • History
    • Physical assessment
    • Laboratory tests
  • Treatment
    • Lifestyle modifications
    • Medications
    • Surgery

ASSESSMENT
  • Difficulty urinating
  • Bladder fullness
  • Weak flow
  • Frequency and urgency
  • Tired during the day due to nocturia
  • Blood pressure: 122/80 mmHg
  • Heart rate: 68
  • Temperature: 98.6 F (37.0 C)
  • Respiratory rate: 16
  • Oxygen saturation: 96% room air
  • Pain: 0/10
  • 300 mL post-void residual 
  • Prostate specific antigen (PSA): 4.5 ng/mL 

NURSING DIAGNOSES
  • Urinary retention related to obstruction of urethra
  • Sleep deprivation related to nocturia
  • Risk for infections related to urinary retention 
  • Deficient knowledge related to treatment regimen and self-care needs

PLANNING
  • Decreased urinary urgency and frequency
  • Decreased nocturia
  • Free of urinary tract infections
  • Verbalize understanding of treatment and self-care needs

IMPLEMENTATION
  • Review new medication
  • Begin bladder diary 
  • Develop toileting schedule 
  • Implement dietary modifications
  • Ensure understanding of urinary tract infection symptoms and when to seek emergency care

EVALUATION
  • Stream has improved
  • 75 mL post-void residual
  • Sleep improved
  • No signs or symptoms of urinary tract infection

Transcript

Watch video only

Martin Lewis is a 68-year-old client who presented to his community health clinic complaining of recurring trips to the bathroom, a frequent urge to urinate, and a weak urine stream that dribbles.

His family physician completed an assessment of his symptoms including a digital rectal exam.

A diagnosis of benign prostatic hyperplasia or BPH is suspected.

The physician ordered several laboratory tests including a basic metabolic panel, prostate specific antigen, and urinalysis to help confirm the diagnosis.

After completing these tests, Martin returns to the clinic two weeks later for a follow-up appointment.

Benign prostatic hyperplasia, or BPH, is a condition where noncancerous cells in the prostate gland increase in number, enlarging the prostate.

This condition is common in men over 50 and is often considered a normal part of aging.

By the age of 60 around 50% of men develop BPH, and over 90% have it by the age of 85.

Other risk factors for developing BPH include obesity, sedentary lifestyle, and family history of BPH.

The exact cause of BPH is not well understood, but current understanding is that environmental and genetic factors play a role along with the influence of the sex hormones tesosterone, dihydrotestosterone, or DHT, and estrogen.

Whatever the cause, the hyperplastic growth of prostatic smooth muscle and epithelial tissue enlarges the prostate which then compresses the urethra, obstructing the flow of urine.

BPH can be asymptomatic, but when symptoms are present, they include lower urinary tract symptoms, such as urinary urgency, hesitancy, which is trouble initiating urination, a weak urine stream, dribbling and straining to urinate, and nocturia.

These symptoms significantly impair quality of life.

If the bladder isn't emptied completely it can eventually cause kidney damage and even lead to kidney failure if not treated.

Also, the stasis of urine in the bladder increases the chance of kidney stones forming and it promotes bacterial growth which can lead to urinary tract infections or prostatitis, which is an infection in the prostate.

Fortunately, BPH does not increase the risk of developing cell mutations that lead to prostate cancer.

Benign prostatic hyperplasia is diagnosed by history and physical examination with a digital rectal examination, which is where a finger is inserted into the rectum to feel the prostate against the anterior wall of the rectum.

Levels of prostate specific antigen, or PSA, which is a substance produced by healthy prostate cells, are also elevated in benign prostatic hyperplasia, since there are more cells making the PSA.

A bladder scanner, which is a portable hand-held ultrasound device, can determine the post void residual volume which is the amount of urine left in the bladder after urinating.

Post void residual volume of greater than 100mL suggests urinary retention.

If an infection is suspected, a urine sample is collected for urinalysis and culture.

Treatment of BPH focuses on relieving the obstruction and allowing the urine to flow normally.

For mild symptoms, lifestyle changes may be enough to manage symptoms, such as avoiding liquids 1 to 2 hours before bedtime to reduce nocturia, retraining the bladder by scheduling regularly timed toileting, and attempting urination in complete privacy.

Placing feet solidly on the floor helps relax the pelvic muscles and encourages voiding, and double voiding promotes more efficient bladder evacuation.

This involves waiting for a few minutes, urinating, then trying to empty the bladder again.

Treatments include medications like alpha blockers, such as tamsulosin, which relax the muscles near the prostate and relieve the pressure on the urethra, allowing urine to follow more easily.

Other medications like finasteride, a 5α-reductase inhibitor, reduce the size of the prostate by inhibiting the conversion of testosterone into dihydrotestosterone.

If medications are not enough to relieve symptoms, there are surgical procedures that can help.

This includes techniques to ablate, or destroy, prostatic tissue using procedures such as transurethral resection of the prostate, which uses electrocautery energy; aquablation, that uses high pressure saline; and photoselective vaporization of the prostate, that uses laser energy.

Another procedure, a transurethral incision of the prostate, is where prostate tissue is left in place, but the urethra is widened.

In certain cases a prostatectomy, where all the prostate tissue is removed, is performed.

Okay, let’s get back to our client Martin and perform an assessment.

You enter the examination room where Martin has been waiting and introduce yourself as the registered nurse, wash your hands, and confirm his identity.

You ask Martin how he is feeling today, and he responds that he has been feeling fine, but during the past several months he’s been having difficulty urinating.

He says he used the bathroom just 10 minutes ago but his bladder still feels full.

Sometimes he has to push to get the flow started, and the flow is weak.

He often has to start and stop while urinating.

Sources

  1. "Ackley and Ladwig’s Nursing Diagnosis Handbook: An Evidence-Based Guide to Planning Care, 13th edition" Mosby (2022)
  2. "Benign prostatic hyperplasia - what do we know?" BJU Int (2021)
  3. "What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?" World J Urol (2019)
  4. "Critical Care Nursing: Diagnosis and Management, 9th edition" Elsevier (2021)
  5. "Harrison’s Principles of Internal Medicine, 21st edition" McGraw Hill / Medical (2022)
  6. "Current Treatment for Benign Prostatic Hyperplasia" Dtsch Arztebl Int (2020)
  7. "Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review" Gerontology (2019)